Observational studyBritish journal of haematology2026
The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.
Observational study in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Primary central nervous system lymphoma (PCNSL) has poor outcomes despite high-dose methotrexate-based therapy. The Endothelial Activation and Stress Index (EASIX) is associated with prognosis in systemic lymphomas but has not been evaluated in PCNSL. Define the association of baseline EASIX in multivariate analysis with Memorial Sloan Kettering Cancer Center (MSKCC) score risk factors. A multicentre retrospective cohort included 128 immunocompetent adults with biopsy-proven diffuse large B-cell PCNSL. EASIX was calculated and the optimal cut-off (0.751) was determined by receiver operating characteristic (ROC) analysis. The primary end-points were overall survival (OS) and progression-free survival (PFS) in the low-EASIX and high-EASIX groups. The median age was 60 years. High EASIX (≥0.751, n = 55) was associated with Eastern Cooperative Oncology Group (ECOG) ≥2 (p = 0.002), elevated lactate dehydrogenase (LDH) (p < 0.001), deep brain lesions (p = 0.007) and cellular myelocytomatosis oncogene/B-cell lymphoma-2 (MYC/BCL-2) double expression (p = 0.01). After a median follow-up of 37 months, high EASIX was associated with inferior OS (27.4 months vs. not reached; p = 0.001) and PFS (25.6 months vs. not reached; p < 0.001). Multivariable Cox analysis confirmed high EASIX as an independent adverse factor for OS (hazard ratio [HR] 4.75) and PFS (HR 4.99), with additional prognostic discrimination within MSKCC risk groups. Baseline EASIX could potentially improve risk stratification and prognostic modelling in PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.